Rapid Theraptic Scince Lab Inc Financials
This page shows Rapid Theraptic Scince Lab Inc (RTSL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2022 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Rapid Theraptic Scince Lab Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Rapid Theraptic Scince Lab Inc's revenue declined 100% year-over-year, from $534 to $0. This contraction results in a growth score of 0/100.
Rapid Theraptic Scince Lab Inc carries a low D/E ratio of -1.72, meaning only $-1.72 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
Rapid Theraptic Scince Lab Inc's current ratio of 0.05 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Rapid Theraptic Scince Lab Inc passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Rapid Theraptic Scince Lab Inc generates $0.64 in operating cash flow (-$1.2M OCF vs -$1.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Rapid Theraptic Scince Lab Inc generated $0 in revenue in fiscal year 2022. This represents a decrease of 100.0% from the prior year.
Rapid Theraptic Scince Lab Inc reported -$1.8M in net income in fiscal year 2022. This represents an increase of 37.4% from the prior year.
Cash & Balance Sheet
Rapid Theraptic Scince Lab Inc generated -$1.2M in free cash flow in fiscal year 2022, representing cash available after capex. This represents an increase of 52.4% from the prior year.
Rapid Theraptic Scince Lab Inc held $0 in cash against $0 in long-term debt as of fiscal year 2022.
Rapid Theraptic Scince Lab Inc had 8M shares outstanding in fiscal year 2022. This represents an increase of 0.3% from the prior year.
Margins & Returns
Capital Allocation
Rapid Theraptic Scince Lab Inc invested $39K in capex in fiscal year 2022, funding long-term assets and infrastructure. This represents a decrease of 86.6% from the prior year.
RTSL Income Statement
| Metric | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | N/A | $0 | $0 | $0 | N/A | $50 |
| Cost of Revenue | $0 | $0 | N/A | $0 | $0 | $0 | N/A | $0 |
| Gross Profit | $0 | $0 | N/A | $0 | $0 | $0 | N/A | $50 |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $98K+5.9% | $92K | N/A | $346K+182.4% | $122K-84.4% | $783K | N/A | $491K |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | $61K-45.2% | $111K | N/A | $346K-54.8% | $766K+7.3% | $713K | N/A | $658K |
| Income Tax | $0 | $0 | N/A | $0 | $0 | $0 | N/A | $0 |
| Net Income | $46K-75.7% | $191K | N/A | -$227K-516.4% | -$37K+97.7% | -$1.6M | N/A | -$583K |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RTSL Balance Sheet
| Metric | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.1M+2.0% | $2.0M-9.8% | $2.3M-1.4% | $2.3M-5.9% | $2.4M-9.7% | $2.7M+22.3% | $2.2M+8.5% | $2.0M |
| Current Assets | $318K+26.8% | $251K+7.5% | $233K-1.8% | $238K-32.9% | $354K+26.8% | $279K-33.4% | $419K-63.8% | $1.2M |
| Cash & Equivalents | $2K-87.7% | $18K | $0 | $0-100.0% | $112K+240.0% | $33K-82.9% | $192K-79.1% | $920K |
| Inventory | $175K0.0% | $175K0.0% | $175K0.0% | $175K0.0% | $175K0.0% | $175K0.0% | $175K-6.4% | $187K |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.8M-1.2% | $4.9M-9.7% | $5.4M+0.4% | $5.4M+0.5% | $5.3M-5.0% | $5.6M+57.3% | $3.6M+63.1% | $2.2M |
| Current Liabilities | $4.4M-0.8% | $4.5M-10.1% | $5.0M+1.2% | $4.9M+0.9% | $4.9M-5.1% | $5.1M+67.8% | $3.1M+49.3% | $2.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$2.7M+3.5% | -$2.8M+9.7% | -$3.1M-1.8% | -$3.1M-5.8% | -$2.9M+0.8% | -$2.9M-112.9% | -$1.4M-727.6% | -$167K |
| Retained Earnings | -$10.1M+0.5% | -$10.1M+1.9% | -$10.3M+0.5% | -$10.4M-2.2% | -$10.1M-0.4% | -$10.1M-18.5% | -$8.5M-16.6% | -$7.3M |
RTSL Cash Flow Statement
| Metric | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7K+82.5% | -$42K+88.1% | -$352K-112.8% | -$165K-353.8% | $65K+109.3% | -$699K-26.7% | -$552K+22.4% | -$711K |
| Capital Expenditures | $0 | $0+100.0% | -$316K-31564700.0% | $1-100.0% | $320K+807.8% | $35K-79.9% | $175K+126.6% | $77K |
| Free Cash Flow | -$7K+82.5% | -$42K+93.7% | -$668K-303.7% | -$165K+35.0% | -$254K+65.4% | -$735K-1.0% | -$727K+7.7% | -$788K |
| Investing Cash Flow | $0 | $0-100.0% | $316K+31564700.0% | -$1+100.0% | -$320K-807.8% | -$35K+79.9% | -$175K-126.6% | -$77K |
| Financing Cash Flow | -$8K-113.6% | $59K+63.1% | $36K-31.6% | $53K-84.0% | $334K-42.0% | $575K | $0-100.0% | $1.7M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RTSL Financial Ratios
| Metric | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 100.0% |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1166884.0% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 2.2%-7.2pp | 9.4% | N/A | -9.9%-8.4pp | -1.5%+57.2pp | -58.7% | N/A | -28.8% |
| Current Ratio | 0.07+0.0 | 0.060.0 | 0.050.0 | 0.05-0.0 | 0.07+0.0 | 0.05-0.1 | 0.14-0.4 | 0.57 |
| Debt-to-Equity | -1.76-0.0 | -1.720.0 | -1.72+0.0 | -1.74+0.1 | -1.83+0.1 | -1.92+0.7 | -2.59+10.6 | -13.15 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1576422.0% |
Note: Shareholder equity is negative (-$3.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.05), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Rapid Theraptic Scince Lab Inc's annual revenue?
Rapid Theraptic Scince Lab Inc (RTSL) reported $0 in total revenue for fiscal year 2022. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Rapid Theraptic Scince Lab Inc's revenue growing?
Rapid Theraptic Scince Lab Inc (RTSL) revenue declined by 100% year-over-year, from $534 to $0 in fiscal year 2022.
Is Rapid Theraptic Scince Lab Inc profitable?
No, Rapid Theraptic Scince Lab Inc (RTSL) reported a net income of -$1.8M in fiscal year 2022.
What is Rapid Theraptic Scince Lab Inc's free cash flow?
Rapid Theraptic Scince Lab Inc (RTSL) generated -$1.2M in free cash flow during fiscal year 2022. This represents a 52.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Rapid Theraptic Scince Lab Inc's operating cash flow?
Rapid Theraptic Scince Lab Inc (RTSL) generated -$1.2M in operating cash flow during fiscal year 2022, representing cash generated from core business activities.
What are Rapid Theraptic Scince Lab Inc's total assets?
Rapid Theraptic Scince Lab Inc (RTSL) had $2.3M in total assets as of fiscal year 2022, including both current and long-term assets.
What are Rapid Theraptic Scince Lab Inc's capital expenditures?
Rapid Theraptic Scince Lab Inc (RTSL) invested $39K in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.
What is Rapid Theraptic Scince Lab Inc's current ratio?
Rapid Theraptic Scince Lab Inc (RTSL) had a current ratio of 0.05 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.
What is Rapid Theraptic Scince Lab Inc's debt-to-equity ratio?
Rapid Theraptic Scince Lab Inc (RTSL) had a debt-to-equity ratio of -1.72 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Rapid Theraptic Scince Lab Inc's return on assets (ROA)?
Rapid Theraptic Scince Lab Inc (RTSL) had a return on assets of -79.6% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.
What is Rapid Theraptic Scince Lab Inc's cash runway?
Based on fiscal year 2022 data, Rapid Theraptic Scince Lab Inc (RTSL) had $0 in cash against an annual operating cash burn of $1.2M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Rapid Theraptic Scince Lab Inc's debt-to-equity ratio negative or unusual?
Rapid Theraptic Scince Lab Inc (RTSL) has negative shareholder equity of -$3.1M as of fiscal year 2022, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Rapid Theraptic Scince Lab Inc's Piotroski F-Score?
Rapid Theraptic Scince Lab Inc (RTSL) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Rapid Theraptic Scince Lab Inc's earnings high quality?
Rapid Theraptic Scince Lab Inc (RTSL) has an earnings quality ratio of 0.64x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Rapid Theraptic Scince Lab Inc?
Rapid Theraptic Scince Lab Inc (RTSL) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.